Find a Doctor

Frank S. Hodi
FH
Areas of Expertise

Frank S. Hodi

Dana-Farber Cancer Institute, Inc.
Oncology, Internal Medicine
Male
Practicing approx. 29 years

Bio

Frank Hodi is an Oncologist and an Internal Medicine specialist in South Weymouth, Massachusetts. He has been an author on 303 peer reviewed articles and participated in 6 clinical trials in the past 15 years. He is licensed to treat patients in MA.

Areas of Expertise

Contact

101 Columbian St
South Weymouth, MA 02190, US

781-340-8000

Latest Advances

Latest Advance
Study
  • Condition: Colitis
  • Journal: Cancer
  • Treatment Used: Vitamin D
  • Number of Patients: 213
  • Published —
The study researched the effects of vitamin D on patients with immune checkpoint inhibitor-induced colitis.
Latest Advance
Study
  • Condition: Advanced Melanoma
  • Journal: Annals of oncology : official journal of the European Society for Medical Oncology
  • Treatment Used: Pembrolizumab
  • Number of Patients: 655
  • Published —
This analysis evaluated outcomes of pembrolizumab treatment for patients with advanced melanoma.
Latest Advance
Study
  • Condition: Resected High-Risk Melanoma
  • Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • Treatment Used: Ipilimumab vs. High-Dose Interferon
  • Number of Patients: 1670
  • Published —
This study evaluated the safety and effectiveness of ipilimumab versus high-dose interferon in patients with resected high-risk melanoma.
Latest Advance
Study
  • Condition: Advanced Melanoma
  • Journal: The New England journal of medicine
  • Treatment Used: Combined Nivolumab and Ipilimumab
  • Number of Patients: 0
  • Published —
This study reported outcomes for nivolumab plus ipilimumab or nivolumab alone in patients with advanced melanoma.
Latest Advance
Study
  • Condition: Advanced Melanoma
  • Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • Treatment Used: Nivolumab and Ipilimumab vs. Nivolumab or Ipilimumab
  • Number of Patients: 1077
  • Published —
This study analyzed the outcomes of patients with advanced melanoma treated with nivolumab and ipilimumab together versus nivolumab alone or ipilimumab alone.
Latest Advance
Study
  • Condition: Metastatic Melanoma
  • Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
  • Treatment Used: Atezolizumab
  • Number of Patients: 45
  • Published —
This study evaluated the long-term safety and activity of atezolizumab in patients with metastatic melanoma.
Latest Advance
Study
  • Condition: BRAF-Mutated Melanoma Patients
  • Journal: Nature medicine
  • Treatment Used: Atezolizumab plus Cobimetinib and Vemurafenib
  • Number of Patients: 0
  • Published —
This study evaluated the safety and anti-tumor activity of combining atezolizumab (anti-PD-L1) with vemurafenib (BRAF inhibitor), or cobimetinib (MEK inhibitor)?plus?vemurafenib, in patients with BRAFV600-mutated metastatic melanoma.
Latest Advance
Study
  • Condition: Immune-Checkpoint Inhibitor-Related Thyroid Disorders
  • Journal: Cancer immunology research
  • Treatment Used: High-Dose Glucocorticoids (HDG)
  • Number of Patients: 151
  • Published —
This study analyzed the impact of glucocorticoid therapy on the outcome of immune-checkpoint inhibitor (ICI)-induced thyroid disorders.
Latest Advance
Study
  • Condition: Advanced Melanoma
  • Journal: Annals of oncology : official journal of the European Society for Medical Oncology
  • Treatment Used: Pembrolizumab
  • Number of Patients: 655
  • Published —
This study tested the safety and efficacy of using pembrolizumab to treat patients with advanced melanoma.
Latest Advance
Study
  • Condition: Advanced melanoma
  • Journal: The Lancet. Oncology
  • Treatment Used: Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone
  • Number of Patients: 945
  • Published —
The aim of this report is to determine the effects of Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone on advanced melanoma.
Latest Advance
Study
  • Condition: Metastatic Uveal Melanoma
  • Journal: Melanoma research
  • Treatment Used: Ganetespib (HSP90 Inhibitor)
  • Number of Patients: 17
  • Published —
This study determined the safety and efficacy of using ganetespib to treat metastatic uveal melanoma.
Latest Advance
Study
  • Condition: Advanced mucosal melanoma
  • Journal: British journal of cancer
  • Treatment Used: Pembrolizumab
  • Number of Patients: 1567
  • Published —
This study assessed efficacy of Pembrolizumab in patients with advanced mucosal melanoma.
Latest Advance
Study
  • Condition: Melanoma Metastatic To The Brain
  • Journal: The New England journal of medicine
  • Treatment Used: combined Nivolumab and Ipilimumab
  • Number of Patients: 94
  • Published —
The purpose of the study was to evaluate the efficacy and safety of nivolumab plus ipilimumab in patients with melanoma who had untreated brain metastases
Latest Advance
Study
  • Condition: Non-small-cell lung cancer
  • Journal: European journal of cancer (Oxford, England : 1990)
  • Treatment Used: Atezolizumab combined with platinum-based doublet chemotherapy
  • Number of Patients: 76
  • Published —
This study evaluated the long-term effects of atezolizumab combined with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer.

Clinical Trials

Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Biological
  • Participants: 200
  • Start Date: October 17, 2018
An Exploratory Study of Nivolumab With or Without Ipilimumab According to the Percentage of Tumoral CD8 Cells in Participants With Advanced Metastatic Cancer
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2/Phase 3
  • Intervention Type: Biological
  • Participants: 600
  • Start Date: September 10, 2015
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1
  • Intervention Type: Biological
  • Participants: 78
  • Start Date: March 13, 2015
A Phase 1 Trial of MK-3475 Plus Ziv-Aflibercept in Patients With Advanced Solid Tumors

All Publications
View All

Publication
Study
  • Journal: Cancer cell
  • Published —
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma.
Publication
Study
  • Journal: Melanoma research
  • Published —
Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218).

Contact

101 Columbian St
South Weymouth, MA 02190, US

781-340-8000

Affiliations

  • Dana-Farber Cancer Institute
  • Brigham And Women's Hospital

Credentials

  • Graduate InstitutionJs Weill Medical College, Cornell University
    1992
  • Licenses
    Internal Medicine in MA
  • Board Certifications
    Medical Oncology
    Internal Medicine

Insurance

Contact them to find out if they accept your insurance plan.